AI brief of an SEC Form 8-K · Collegium Pharmaceutical (COLL)

Collegium Q1 revenue rises 9% to $193.5 million; 2026 guidance reaffirmed

Positive Impact 3 of 5 earnings Written later

Collegium reported first-quarter 2026 product revenues, net of $193.5 million, up 9% from a year earlier, with GAAP net income of $14.5 million compared with $2.4 million in the prior-year quarter. The company reaffirmed its full-year 2026 guidance for its current business, which excludes the pending $650 million cash acquisition of AZSTARYS, expected to close in the second quarter of 2026.

Key points

  • Product revenues, net were $193.5 million, up 9% from $177.8 million in the first quarter of 2025.
  • GAAP net income was $14.5 million, or $0.40 per diluted share, versus $2.4 million, or $0.07 per diluted share, a year earlier.
  • JORNAY PM net revenue was $38.9 million, up 36% year-over-year.
  • Full-year 2026 product revenues, net guidance of $805 million to $825 million was reaffirmed; the company expects to update guidance after the AZSTARYS acquisition closes.

The filing

CompanyCollegium Pharmaceutical (COLL)
Form8-K, current report
Filed with the SECMay 7, 2026, 7:33 AM ET
Accession number0001628280-26-031694

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.